Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Diabetes Spectr ; 36(4): 398-402, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38024220

RESUMO

Background: Health insurance coverage type differs significantly by socioeconomic status and racial group in the United States. The aim of this study was to determine whether publicly insured children and young adults with type 1 diabetes were more likely to experience adverse outcomes compared with privately insured patients with acute coronavirus disease 2019 (COVID-19) infections. Methods: Data from 619 patients with previously established type 1 diabetes who were <24 years of age with acute COVID-19 infections were analyzed from the T1D Exchange COVID-19 surveillance registry. Data for the registry was collected from 52 endocrinology clinics across the United States using an online survey tool. Each site completed the survey using electronic health record data between April 2020 and December 2021. Results: Of the 619 patients included in this study, 257 had public insurance and 362 had private insurance. Of the 257 publicly insured patients with COVID-19, 57 reported severe adverse outcomes (22%), defined as diabetic ketoacidosis (DKA) or severe hypoglycemia. In comparison, there were 25 reported adverse outcomes (7%) among the 362 privately insured patients. Conclusion: Our data reveal high rates of hospitalization and DKA among publicly insured racial/ethnic minority children and young adults with type 1 diabetes and COVID-19.

2.
J Neurosurg ; 100(2 Suppl Pediatrics): 212-6, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-14758953

RESUMO

The authors describe a unique case of a 2-year-old boy with a hypothalamic hamartoma secreting corticotropin-releasing hormone (CRH). The patient presented with a history of behavioral disturbances progressing over 12 months. His neurological status was intact. Magnetic resonance imaging demonstrated a 1.8 x 1.6 x 1.2-cm isointense, nonenhancing hypothalamic lesion. Endocrinological workup revealed elevated serum CRH and adrenocorticotropic hormone levels, nonsuppression with low-dose dexamethasone, and partial suppression with high-dose dexamethasone. He underwent tumor resection via a right frontotemporal craniotomy. Pathological examination of the tissue confirmed a hypothalamic hamartoma with CRH immunostaining. Postoperatively, his hormone levels normalized and his behavioral disturbances abated. The radiographic and clinical characteristics of hypothalamic hamartomas are reviewed and therapeutic considerations discussed.


Assuntos
Hormônio Liberador da Corticotropina/metabolismo , Hamartoma/diagnóstico , Doenças Hipotalâmicas/diagnóstico , Hormônio Adrenocorticotrópico/sangue , Transtornos do Comportamento Infantil/sangue , Transtornos do Comportamento Infantil/etiologia , Pré-Escolar , Dexametasona , Diagnóstico Diferencial , Hamartoma/sangue , Hamartoma/patologia , Hamartoma/cirurgia , Humanos , Hidrocortisona/sangue , Doenças Hipotalâmicas/sangue , Doenças Hipotalâmicas/patologia , Doenças Hipotalâmicas/cirurgia , Hipotálamo/patologia , Hipotálamo/cirurgia , Imageamento por Ressonância Magnética , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA